 |
| |
|
¿Ãºñ¾Æ¼ÖÁÖ ALLVIASOL INJ[D-sorbitol , Glycine , Histidine HCl monohydrate , L-alanine , L-arginine , L-isoleucine , L-leucine , L-methionin
|
|
Àü¹®ÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹ÌȲ»ö, Ȳ»ö Åõ¸í¿ë¾×À» ¹«»ö Åõ¸í¿ë±â¿¡ ÃæÁøÇÑ °Í [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
200, 250, 500, 1000§¢ |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ »óŽÃÀÇ ¾Æ¹Ì³ë»ê º¸±Þ : Àú ´Ü¹éÇ÷Áõ , Àú ¿µ¾ç»óÅ , ¼ö¼úÀüÈÄ
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Glycine][L-Alanine][L-Arginine][L-Isoleucine][L-Leucine][L-Methionine][L-Phenylalanine][L-Proline][L-Threonine][L-Tryptophan][L-Valine][Vitamin B2 (Riboflavin)][Vitamin B6 (Pyridoxine)]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
º¸Åë ¼ºÀÎÀº ÃѾƹ̳ë»êÀ¸·Î üÁß kg ´ç 1 ÀÏ 1-1.5g À» ÃÖ´ë¿ë·®À¸·Î Á¤¸Æ³» Á¡ÀûÁÖ»çÇÏ°í ±× Åõ¿©¼Óµµ´Â 60 ºÐ°£¿¡ ÃÑ ¾Æ¹Ì³ë»êÀ¸·Î¼ 10g Á¤µµÀÇ ³óµµ°¡ ¹Ù¶÷Á÷Çϸç 1 ºÐ°£ 30-40 ÀûÀ» Á¡Àû ÁÖ»çÇÔÀ» ¿øÄ¢À¸·Î ÇÑ´Ù.
´Ù¸¸, ¼Ò¾Æ , ³ëÀÎ , ´Ü¹é¿ä±¸·®ÀÌ ¸¹Àº È»óȯÀÚ µîÀÇ °æ¿ì´Â ¿ë·® ¹× ÁÖÀÔ¼Óµµ¸¦ ÀûÀýÈ÷ Á¶ÀýÇÏ¿© Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù .
|
| ±Ý±â |
- °£¼ºÈ¥¼ö ¶Ç´Â °£¼ºÈ¥¼öÀÇ ¿ì·Á°¡ Àִ ȯÀÚ
- ÁßÁõ ½ÅÀå¾Ö ȯÀÚ , °íÁú¼ÒÇ÷Áõ ȯÀÚ
- Áú¼Ò ÀÌ¿ëÀ» ÀúÇØÇÏ´Â ´ë»ç Àå¾Ö ȯÀÚ
- ¼Ò¸ð¼º ½ÉºÎÀüÁõ
- Æó¼öÁ¾
- ÇÌ´¢Áõ , ¹«´¢Áõ ȯÀÚ
- °ú³ªÆ®·ý Ç÷Áõ°ú ¿°¼ÒÇ÷Áõ ¶Ç´Â ¾ËÄ®·Î½Ã½ºÈ¯ÀÚ
- ÀúÀ强 Å»¼öÁõȯÀÚ
- Á¥»ê¾Æ½Ãµµ½Ã½º , ¸ÞÄ¥¾ËÄÚ¿ÃÁßµ¶Áõ
- À¯Àü¼º °ú´çºÒ³»ÁõȯÀÚ
- ¹æ½Çºí·° , ÁßÁõ±Ù¹«·ÂÁõ
|
| ½ÅÁßÅõ¿© |
- °íµµÀÇ ¾Æ½Ãµµ½Ã½º ȯÀÚ
- ¿ïÇ÷¼º ½ÉºÎÀü ȯÀÚ
- ¿ïÇ÷¼º ½ÉºÎÀü , ÁßÁõ ½ÉºÎÀü , ³ªÆ®·ý Àú·ù·Î ÀÎÇÑ ºÎÁ¾ ȯÀÚ
- °úÄ®·ýÇ÷Áõ , ÁßÁõ ½ÅºÎÀü , Ä÷ýÀú·ù
- ¿äºØÁõȯÀÚ
- °£Àå¾Ö , ½ÅÀå¾Ö°¡ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- °ú¹ÎÁõ :
µå¹°°Ô ¹ßÁøµî °ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç , ÀÌ·± °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù .
¼Òȱâ :¶§¶§·Î ±¸¿ª , ±¸Åä µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù .
¼øÈ¯±â :¶§¶§·Î ÈäºÎ ºÒÄè°¨ , ½É°èÇ×Áø , ºó¸Æ , Ç÷¾Ð°ÇÏ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù .
´ë·®±Þ¼ÓÅõ¿© :´ë·® ±Þ¼Ó Åõ¿©ÇÒ °æ¿ì ¾Æ½Ãµµ½Ã½º°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù .
±âŸ :°¡²û ¿°¨ , Ç÷°üÅë , ¿ÀÇÑ , ¹ß¿ , µÎÅë , È£Èí°ø¶õ , È£ÈíÁ¤Áö , ¼ï , ±â°üÁö °æÃà , ¿ä·Î °æÃàÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù .
¸»ÃÊ Ç÷°ü È®ÀåÁõÀÌ ³ªÅ¸³´Ù´Â º¸°í°¡ ÀÖ´Ù .
´ÙÀ½ÀÇ ´ë»ç¼º ÇÕº´ÁõÀÌ ³ªÅ¸³´Ù´Â º¸°í°¡ ÀÖ´Ù .
- ´ë»ç¼º ¾Æ½Ãµµ½Ã½º , ÀúÀλ꿰Ç÷Áõ , ¾ËÄ®·Î½Ã½º , °íÇ÷´çÁõ , ´ç´¢º´ , »ïÅõÀû ÀÌ´¢ ¹× Å»¼öÁõ , ¹Ýµ¿¼º ÀúÇ÷´ç , °£È¿¼Ò »ó½Â , ºñŸ¹Î °áÇÌ ¹× ºñŸ¹Î °úÀ× , ÀüÇØÁú ºÒ±ÕÇü , ¼Ò¾Æ °í¾Ï¸ð´Ï¾Æ Ç÷Áõ
°£ºÎÀü ¹× ½ÅºÎÀü ȯÀÚ´Â BUN ÀÇ »ó½ÂÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù .
°£ºÎÀü ȯÀÚ´Â Ç÷û ¾Æ¹Ì³ë»ê ºÒ±ÕÇü , ´ë»ç¼º ¾ËÄ®·Î½Ã½º , Àü½ÅÁú¼ÒÇ÷Áõ , °ú¾Ï¸ð´Ï¾ÆÇ÷Áõ , Áö°¢»ó½Ç , È¥¼ö µîÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
Åׯ®¶ó½ÎÀÌŬ¸°°ú º´¿ë Åõ¿©½Ã ¼ö¾× ¾Æ¹Ì³ë»êÀÇ ´Ü¹éÀý¾àÈ¿°ú¸¦ °¨¼Ò½Ãų ¼ö ÀÖ´Ù . Ä®½·¿°À» Á¤¸ÆÁÖ»çÇÏ¸é ¸¶±×³×½·¿°À» ¼®Ãâ½ÃŲ´Ù |
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(sorbitol; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
D-Sorbitol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Nicotinamide¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Glycine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS.
L-alanine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance.
L-arginine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.
L-isoleucine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
L-leucine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
L-methionine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability.
L-phenylalanine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The mechanism of L-phenylalanine's putative antidepressant activity may be accounted for by its precursor role in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects. The mechanism of L-phenylalanine's possible antivitiligo activity is not well understood. It is thought that L-phenylalanine may stimulate the production of melanin in the affected skin
L-proline¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Glycogenic, by L-Proline oxidase in the kidney, it is ring-opened and is oxidized to form L-Glutamic acid. L-Ornithine and L-Glutamic acid are converted to L-Proline via L-Glutamic acid-gamma-semialdehyde. It is contained abundantly in collagen, and is intimately involved in the function of arthrosis and chordae.
L-threonine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. May help combat mental illness and may be very useful in indigestion and intestinal malfunctions. Also, threonine prevents excessive liver fat. Nutrients are more readily absorbed when threonine is present.
L-tryptophan¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ A number of important side reactions occur during the catabolism of tryptophan on the pathway to acetoacetate. The first enzyme of the catabolic pathway is an iron porphyrin oxygenase that opens the indole ring. The latter enzyme is highly inducible, its concentration rising almost 10-fold on a diet high in tryptophan. Kynurenine is the first key branch point intermediate in the pathway. Kynurenine undergoes deamniation in a standard transamination reaction yielding kynurenic acid. Kynurenic acid and metabolites have been shown to act as antiexcitotoxics and anticonvulsives. A second side branch reaction produces anthranilic acid plus alanine. Another equivalent of alanine is produced further along the main catabolic pathway, and it is the production of these alanine residues that allows tryptophan to be classified among the glucogenic and ketogenic amino acids. The second important branch point converts kynurenine into 2-amino-3-carboxymuconic semialdehyde, which has two fates. The main flow of carbon elements from this intermediate is to glutarate. An important side reaction in liver is a transamination and several rearrangements to produce limited amounts of nicotinic acid, which leads to production of a small amount of NAD+ and NADP+.
L-valine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
|
| Pharmacology |
Glycine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.
L-alanine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids.
L-arginine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.
L-isoleucine¿¡ ´ëÇÑ Pharmacology Á¤º¸ They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert.
L-leucine¿¡ ´ëÇÑ Pharmacology Á¤º¸ An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine
L-methionine¿¡ ´ëÇÑ Pharmacology Á¤º¸ L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity.
L-phenylalanine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used by the brain to produce Norepinephrine, a chemical that transmits signals between nerve cells and the brain; keeps you awake and alert; reduces hunger pains; functions as an antidepressant and helps improve memory.
L-proline¿¡ ´ëÇÑ Pharmacology Á¤º¸ L-Proline is a major amino acid found in cartilage and is important for maintaining youthful skin as well as repair of muscle, connective tissue and skin damage. It is also essential for the immune system, and for necessary balance of this formula. It is an essential component of collagen and is important for proper functioning of joints and tendons. L-Proline is extremely important for the proper functioning of joints and tendons. Helps maintain and strengthen heart muscles.
L-threonine¿¡ ´ëÇÑ Pharmacology Á¤º¸ L-Threonine is an essential amino acid that helps to maintain the proper protein balance in the body. It is important for the formation of collagen, elastin, and tooth enamel, and aids liver and lipotropic function when combined with aspartic acid and methionine.
L-tryptophan¿¡ ´ëÇÑ Pharmacology Á¤º¸ Tryptophan is critical for the production of the body's proteins, enzymes and muscle tissue. It is also essential for the production of niacin, the synthesis of the neurotransmitter serotonin and melatonin. Tryptophan supplements can be used as natural relaxants to help relieve insomnia. Tryptophan can also reduce anxiety and depression and has been shown to reduce the intensity of migraine headaches. Other promising indications include the relief of chronic pain, reduction of impulsivity or mania and the treatment of obsessive or compulsive disorders. Tryptophan also appears to help the immune system and can reduce the risk of cardiac spasms. Tryptophan deficiencies may lead to coronary artery spasms. Tryptophan is used as an essential nutrient in infant formulas and intravenous feeding. Tryptophan is marketed as a prescription drug (Tryptan) for those who do not seem to respond well to conventional antidepressants. It may also be used to treat those afflicted with seasonal affective disorder (a winter-onset depression). Tryptopan serves as the precursor for the synthesis of serotonin (5-hydroxytryptamine, 5-HT) and melatonin (N-acetyl-5-methoxytryptamine).
L-valine¿¡ ´ëÇÑ Pharmacology Á¤º¸ L-valine is a branched-chain essential amino acid (BCAA) that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway. Valine is one of three branched-chain amino acids (the others are leucine and isoleucine) that enhance energy, increase endurance, and aid in muscle tissue recovery and repair. This group also lowers elevated blood sugar levels and increases growth hormone production. Supplemental valine should always be combined with isoleucine and leucine at a respective milligram ratio of 2:1:2. It is an essential amino acid found in proteins; important for optimal growth in infants and for growth in children and nitrogen balance in adults. The lack of L-valine may influence the growth of body, cause neuropathic obstacle, anaemia. It has wide applications in the field of pharmaceutical and food industry.
|
| Metabolism |
L-isoleucine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
L-methionine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Glutamine SynthetaseMethylenetetrahydrofolate reductase
L-proline¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Proline oxidase
L-tryptophan¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Tryptophan 2,3-dioxygenaseAromatic-L-amino-acid decarboxylase (AADC)
L-valine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Catechol O-methyltransferase (COMT)
|
| Absorption |
Glycine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine via an active transport mechanism.
L-arginine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism.
L-isoleucine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine by a sodium-dependent active-transport process
L-methionine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the lumen of the small intestine into the enterocytes by an active transport process.
L-phenylalanine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine by a sodium dependent active transport process.
L-valine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed from the small intestine by a sodium-dependent active-transport process.
|
| Pharmacokinetics |
Pyridoxine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
- ´ë»ç : °£¿¡¼ 4-pyridoxic acid·Î ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 15-20ÀÏ
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1.25 ½Ã°£
- ¼Ò½Ç : 4-pyridoxic acid·Î ½Å¹è¼³µÇ¸ç, ¼Ò·® (¾à 2%)Àº ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
Riboflavin sodium phosphateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö :
- À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
- À½½Ä¹°¿¡ ÀÇÇØ Èí¼ö¾çÀÌ Áõ°¡ÇÑ´Ù.
- °£¿°, °£°æÈ, ´ã°üÆó»öÀÌ Àִ ȯÀÚ¿¡¼ Èí¼ö°¡ °¨¼ÒÇÑ´Ù.
- ºÐÆ÷ : ü³» ¸ðµç Á¶Á÷¿¡ ³Î¸® ºÐÆ÷ÇÑ´Ù.
- ¹Ý°¨±â :
- Ãʱ⠻ó : 1.4 ½Ã°£
- ¸»±â »ó : 14½Ã°£
- ¼Ò½Ç : ¹Ìº¯Èü·Î ½Å¹è¼³µÇ´Â ¾çÀº ¾à 9%ÀÌ´Ù.
Aminoacetic Acid(Glycine)ÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : GlycineÀº ´Ü¹é, creatinine, glycocholic acid, glutathione, uric acid, heme µîÀÇ ÇÕ¼º¿¡ °ü¿©ÇÑ´Ù.
ü³»¿¡¼ÀÇ ºÐÇØ´Â ¿©·¯´Ü°è·Î ÀÌ·ç¾îÁö¸ç ÁÖµÈ °æ·Î´Â °¡¿ªÀûÀÎ »êÈÀû ºÐÇØÀÌ´Ù.
SerineÀÌ Á¤»óÀûÀÎ ºÐÇØ»ê¹°ÀÌ´Ù.
- Ç÷Àå ¹Ý°¨±â : 85ºÐ
L-arginineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ°í Ç÷Áß³óµµ µµ´Þ : °æ±¸ : 2½Ã°£
- ÃÖ´ë È¿°ú ¹ßÇö :
- ´ç´¢ Áø´Ü : Á¤¸ÆÁÖ»ç : 20-45 ºÐ
Ç÷´çÀÇ ÃÖ°í »ó½ÂÀº 20ºÐ ÈÄ¿¡ ³ªÅ¸³ª¸ç, Àν¶¸°ÀÇ ÃÖ´ë »ó½ÂÀº 20-30 ºÐ ÈÄ¿¡ ³ªÅ¸³ª¸ç glucagonÀº 30-45 ºÐ ÈÄ¿¡ ³ªÅ¸³´Ù.
- ¼ºÀåÈ£¸£¸ó º¸À¯ Áø´Ü : Á¤¸ÆÁÖ»ç : 1-2 ½Ã°£
Arginine 30 gÀ» 30ºÐ°£ Á¤¸ÆÁÖ»ç ÈÄ ¼ºÀåÈ£¸£¸óÀÇ ÃÖ´ë »ó½ÂÀÌ ¾à 1-2 ½Ã°£ ÈÄ¿¡ ³ªÅ¸³´Ù.
- ÀÛ¿ë Áö¼Ó ½Ã°£ : Á¤¸ÆÁÖ»ç : 1½Ã°£
- Èí¼ö : À§Àå°ü¿¡¼ Àß Èí¼öµÊ
- ´ë»ç : °£¿¡¼ arginase¿¡ ÀÇÇØ guanidino groupÀÌ °¡¼öºÐÇØµÇ¾î urea¿Í ornithineÀ» »ý¼ºÇÑ´Ù.
OrnithineÀº ±Ã±ØÀûÀ¸·Î glucose »ý¼º¿¡ ÀÌ¿ëµÈ´Ù.
- ¼Ò½Ç : ½ÅÀå : »ç±¸Ã¼·Î ¿©°úµÇ°í ½Å¼¼´¢°üÀ¸·Î ÀçÈí¼öµÈ´Ù.
- ¹Ý°¨±â : 1.2-2 ½Ã°£
L-methionineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : S-adenosylmethionineÀ» °ÅÃÄ homocysteineÀ¸·Î ÀüȯµÈ´Ù. ±× ÈÄ 80%°¡ cystathione, cysteine, taurine, inorganic sulphate·Î Á¡Â÷·Î ´ë»çµÈ´Ù.
NicotinamideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : pellagra : 24½Ã°£
- Èí¼ö : À§Àå°üÀ¸·ÎºÎÅÍ ½Å¼ÓÇÏ°Ô Èí¼öµÈ´Ù.
- ºÐÆ÷ :
- ¸ðµç Á¶Á÷À¸·Î ½Å¼ÓÇÏ°Ô ºÐÆ÷ÇÑ´Ù.
- ÅÂ¾Æ ¹× ½Å»ý¾Æ¿¡¼ÀÇ ³óµµ°¡ ¸ðüÀÇ ³óµµº¸´Ù ³ô´Ù.
- ´ë»ç : °£´ë»ç
- Nicotinamide´Â »ýü ³»¿¡¼ niacinÀÇ ´ë»ç·ÎºÎÅÍ Çü¼ºµÉ ¼ö ÀÖ´Ù.
- Dietrich pathway¸¦ ÅëÇØ È¿¼ÒÀûÀ¸·Î NAD ¹× NADP·Î ÀüȯµÈ´Ù.
- ¹Ý°¨±â : 45ºÐ
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 20-70ºÐ
- ¼Ò½Ç : ¿ë·®ÀÇÁ¸ÀûÀ¸·Î ¹Ìº¯Èü ¹× ´ë»çü·Î¼ ½Å¹è¼³µÈ´Ù. (»ý¸®Àû ¿ë·®¿¡¼´Â ¼Ò·®¸¸ÀÌ ¹Ìº¯Èü·Î ½Å¹è¼³µÇ³ª °í¿ë·® Åõ¿©½Ã ÁÖ·Î ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.)
D-sorbitolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö ½Ã°£ : 0.25-1 ½Ã°£
- Èí¼ö : °æ±¸, Á÷Àå : °ÅÀÇ Èí¼öµÇÁö ¾Ê´Â´Ù.
- ¼Ò½Ç : °£¿¡¼ fructose·Î ´ë»çµÈ´Ù.
|
| Biotransformation |
Glycine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-arginine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized.
L-isoleucine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-methionine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-phenylalanine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. L-phenylalanine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body, where it undergoes metabolic reactions similar to those that take place in the liver.
L-proline¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-threonine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
L-tryptophan¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
L-valine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Glycine¿¡ ´ëÇÑ Toxicity Á¤º¸ ORL-RAT LD50 7930 mg/kg, SCU-RAT LD50 5200 mg/kg, IVN-RAT LD50 2600 mg/kg, ORL-MUS LD50 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole.
L-arginine¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses.
L-isoleucine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs
L-methionine¿¡ ´ëÇÑ Toxicity Á¤º¸ Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis.
L-phenylalanine¿¡ ´ëÇÑ Toxicity Á¤º¸ L-phenylalanine will exacerbate symptoms of phenylketonuria if used by phenylketonurics. L-phenylalanine was reported to exacerbate tardive dyskinesia when used by some with schizophrenia.
L-proline¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
L-tryptophan¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral rat LD50: > 16 gm/kg. Investigated as a tumorigen, mutagen, reproductive effector. Symptoms of overdose include agitation, confusion, diarrhea, fever, overactive reflexes, poor coordination, restlessness, shivering, sweating, talking or acting with excitement you cannot control, trembling or shaking, twitching, and vomiting.
L-valine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs.
|
| Drug Interactions |
Glycine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-arginine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-isoleucine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-methionine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-phenylalanine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-proline¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-tryptophan¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
L-valine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
L-methionine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food.
|
| Drug Target |
[Drug Target]
|
| Description |
D-sorbitol¿¡ ´ëÇÑ Description Á¤º¸ A polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. It is also used in many manufacturing processes, as a pharmaceutical aid, and in several research applications. [PubChem]
Glycine¿¡ ´ëÇÑ Description Á¤º¸ A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem]
L-alanine¿¡ ´ëÇÑ Description Á¤º¸ A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem]
L-arginine¿¡ ´ëÇÑ Description Á¤º¸ An essential amino acid that is physiologically active in the L-form. [PubChem]
L-isoleucine¿¡ ´ëÇÑ Description Á¤º¸ An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem]
L-leucine¿¡ ´ëÇÑ Description Á¤º¸ An essential branched-chain amino acid important for hemoglobin formation. [PubChem]
L-methionine¿¡ ´ëÇÑ Description Á¤º¸ A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. [PubChem]
L-phenylalanine¿¡ ´ëÇÑ Description Á¤º¸ An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]
L-proline¿¡ ´ëÇÑ Description Á¤º¸ A non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. [PubChem]
L-threonine¿¡ ´ëÇÑ Description Á¤º¸ An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. [PubChem]
L-tryptophan¿¡ ´ëÇÑ Description Á¤º¸ An essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals. [PubChem]
L-valine¿¡ ´ëÇÑ Description Á¤º¸ A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway. [PubChem]
Nicotinamide¿¡ ´ëÇÑ Description Á¤º¸ An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. [PubChem]
|
| Dosage Form |
Glycine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IrrigationSolution Intraperitoneal
L-alanine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Not Available
L-arginine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid Intravenous
L-isoleucine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralPowder OralTablet Oral
L-leucine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralPowder OralTablet Oral
L-methionine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralPowder OralTablet OralTablet Oral
L-tryptophan¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralTablet Oral
|
| Drug Category |
D-sorbitol¿¡ ´ëÇÑ Drug_Category Á¤º¸ CatharticsIndicators and ReagentsSweetening Agents
Glycine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementGlycine AgentsMicronutrientNon-Essential Amino Acids
L-alanine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementMicronutrientNon-Essential Amino Acids
L-arginine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Conditionally Essential Amino AcidsDietary supplementMicronutrient
L-isoleucine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
L-leucine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
L-methionine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
L-phenylalanine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
L-proline¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementMicronutrientNon-Essential Amino Acids
L-threonine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementEssential Amino AcidsMicronutrient
L-tryptophan¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antidepressive Agents, Second-GenerationDietary supplementEssential Amino AcidsMicronutrient
L-valine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementsEssential Amino AcidsMicronutrients
Nicotinamide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Vitamin B Complex
|
| Smiles String Canonical |
D-sorbitol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OCC(O)C(O)C(O)C(O)CO
Glycine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NCC(O)=O
L-alanine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(N)C(O)=O
L-arginine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(CCCN=C(N)N)C(O)=O
L-isoleucine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC(C)C(N)C(O)=O
L-leucine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)CC(N)C(O)=O
L-methionine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CSCCC(N)C(O)=O
L-phenylalanine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(CC1=CC=CC=C1)C(O)=O
L-proline¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OC(=O)C1CCCN1
L-threonine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(O)C(N)C(O)=O
L-tryptophan¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(CC1=CNC2=CC=CC=C12)C(O)=O
L-valine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)C(N)C(O)=O
Nicotinamide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(=O)C1=CC=CN=C1
|
| Smiles String Isomeric |
D-sorbitol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Glycine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NCC(O)=O
L-alanine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](N)C(O)=O
L-arginine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H](CCC\N=C(\N)N)C(O)=O
L-isoleucine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC[C@H](C)[C@H](N)C(O)=O
L-leucine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)C[C@@H](N)C(O)=O
L-methionine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CSCC[C@H](N)C(O)=O
L-phenylalanine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H](CC1=CC=CC=C1)C(O)=O
L-proline¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ OC(=O)[C@@H]1CCCN1
L-threonine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H](O)[C@H](N)C(O)=O
L-tryptophan¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O
L-valine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[C@H](N)C(O)=O
Nicotinamide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC(=O)C1=CC=CN=C1
|
| InChI Identifier |
D-sorbitol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
Glycine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H
L-alanine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1/f/h5H
L-arginine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1/f/h11H,8-9H2
L-isoleucine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H
L-leucine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H
L-methionine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/f/h7H
L-phenylalanine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1/f/h11H
L-proline¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1/f/h7H
L-threonine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1/f/h7H
L-tryptophan¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1/f/h14H
L-valine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1/f/h7H
Nicotinamide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)/f/h7H2
|
| Chemical IUPAC Name |
D-sorbitol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol
Glycine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-aminoacetic acid
L-alanine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-aminopropanoic acid
L-arginine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
L-isoleucine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S,3S)-2-amino-3-methylpentanoic acid
L-leucine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-amino-4-methylpentanoic acid
L-methionine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-4-methylsulfanylbutanoic acid
L-phenylalanine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-3-phenylpropanoic acid
L-proline¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-pyrrolidine-2-carboxylic acid
L-threonine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S,3R)-2-amino-3-hydroxybutanoic acid
L-tryptophan¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
L-valine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-3-methylbutanoic acid
Nicotinamide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ pyridine-3-carboxamide
|
| Drug-Induced Toxicity Related Proteins |
LYSINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [¹Ù·Î°¡±â] METHIONINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [¹Ù·Î°¡±â] Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â] Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-07-05
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|